Tekia, Inc. to Present at Medtech Insight and Windhover Information's ``Investment In Innovation (In3) WEST'' Conference, February 23-24, 2006, Irvine, Calif.IRVINE, Calif. -- Tekia, Inc. has announced that it will be presenting on February 23, 2006, at 9:55 a.m. at Medtech Insight and Windhover Information's "Investment In Innovation (In3) WEST: A Preview of Early-Stage Medical Technology Companies" Conference, February 23-24, 2006, at the Hyatt Regency Irvine in Irvine, Calif. Tekia, Inc., a privately owned ophthalmic device company that recently received approval from the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community for its Tek-Clear(TM) Accommodating Intraocular Lens (AIOL). The Tek-Clear(TM) AIOL is used for the treatment of presbyopia Presbyopia Definition The term presbyopia means "old eye" and is a vision condition involving the loss of the eye's ability to focus on close objects. , a condition that affects near vision in many middle-aged and older patients. Presbyopia is caused from the loss of flexibility in the natural lens of the eye as a person ages, usually from age 45 on, and results in the inability to focus on objects up close. The Tek-Clear(TM) AIOL is designed to take advantage of the eye's natural accommodating structures to shift the lens forward and backward, enabling a person to see near and distant objects. The lens could be used during cataract surgery to restore near vision and at the same time correct for other visual disorders, such as farsightedness or nearsightedness nearsightedness or myopia, defect of vision in which far objects appear blurred but near objects are seen clearly. Because the eyeball is too long or the refractive power of the eye's lens is too strong, the image is focused in front of the . It also could be used in pre-cataract patients with presbyopia to restore near and intermediate vision, replacing corrective glasses or contact lens. The Company has developed advanced IOL IOL Intraocular lens, see there technologies and products for the emerging high growth, high margin "private pay" Refractive refractive capacity to refract light. refractive error a difference between the focal length of the cornea and lens, and the length of the eye, resulting in myopia or hyperopia. Intraocular Lens (RIOL) market that is projected to grow 40+% annually from 158 million in 2005 to over 1 billion by 2010. The Company expects to submit to the U.S. Food and Drug Administration two Investigational Device Exemptions (IDE), one for its Tek-Clear(TM) Accommodating Intraocular Lens and another for its Kelman Duet(TM) Phakic IOL during the third quarter of 2006. The Kelman Duet(TM) is designed for the treatment of mid- to high-myopia and hyperopia hyperopia (hī'pərō`pēə): see farsightedness. in non-cataract patients. The Kelman Duet Phakic IOL is implanted in the eye while the natural eye is in place and was co-developed by Tekia and Dr. Charles D. Kelman. The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval process is costly, and for that reason the Company expects to pursue financing options and/or a strategic partner to provide additional resources. The Company also designs, develops, manufactures and distributes Intraocular Lenses to treat visual disorders such as cataracts, myopia myopia: see nearsightedness. , hyperopia and astigmatism astigmatism (əstĭg`mətĭz'əm), type of faulty vision caused by a nonuniform curvature in the refractive surfaces—usually the cornea, less frequently the lens—of the eye. . The company currently distributes all of its products including the Tek-Clear(TM) IOL and the Kelman Duet Phakic IOL in the EU and some South American countries. The company has various advanced lens and materials designs under development to provide eye care patients with higher satisfaction. The company has also filed several patents to protect its intellectual properties and designs. A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. In3 WEST is Medtech Insight's 20th investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512 or 888-202-5939 toll-free in the U.S., e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion